Peptide Lab HQ Research Guide
Livagen
A research-focused compound profile covering Livagen identity, KEDA tetrapeptide research, peptide bioregulator models, liver-cell research context, digestive enzyme activity, concentration reference, preparation reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Livagen |
|---|---|
| Common Research Name | KEDA tetrapeptide |
| Common Synonyms | Lys-Glu-Asp-Ala, H-Lys-Glu-Asp-Ala-OH, KEDA peptide, peptide bioregulator |
| Compound Type | Synthetic ultrashort tetrapeptide / peptide bioregulator research compound |
| CAS Number | Commonly listed as 195875-84-4; verify against supplier COA |
| PubChem CID | 87919683 |
| Amino Acid Length | 4 amino acids |
| Amino Acid Sequence | Lys-Glu-Asp-Ala |
| Short Sequence | KEDA |
| Molecular Formula | C₁₈H₃₁N₅O₉; verify against supplier COA |
| Molecular Weight | Approximately 461.46 g/mol; verify against supplier COA |
| Research Category | Peptide bioregulator, liver-cell model, digestive enzyme activity, chromatin structure, gene-expression, immune-response, and aging-marker research |
| Research Context | Commonly discussed in ultrashort peptide bioregulator research involving hepatocyte culture, protein synthesis, digestive enzyme activity, endogenous peptide metabolism, chromatin dynamics, and cellular aging models. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Livagen is commonly discussed in controlled research models involving KEDA tetrapeptide activity, peptide bioregulation, hepatocyte culture, protein-synthesis observations, digestive enzyme activity, endogenous peptide metabolism, chromatin dynamics, gene-expression context, and cellular aging-marker research.
Peptide Bioregulator Research
Livagen is commonly positioned within ultrashort peptide bioregulator research, where short amino acid sequences are studied for tissue-specific signaling and gene-expression related effects.
Hepatocyte Culture Models
Livagen has been discussed in rat liver-cell culture research involving protein-synthesis activity and age-associated cellular changes.
Digestive Enzyme Research
Livagen appears in research involving age-dependent digestive enzyme activity and peptide interaction with enzyme systems in gastrointestinal research models.
Endogenous Peptide Metabolism
Published research has evaluated Livagen in relation to enkephalin-degrading enzymes, endogenous opioid peptide metabolism, and serum enzyme activity.
Chromatin & Gene-Expression Context
Livagen is commonly discussed in peptide bioregulator references involving chromatin structure, cellular gene-expression patterns, and age-associated epigenetic models.
Aging-Marker Research
Short peptide bioregulator research often evaluates age-related cellular markers, protein synthesis, enzyme activity, tissue response, and cellular regulatory patterns.
Research Scope
These applications are provided for educational and research-reference purposes only. Livagen research is limited compared with major peptide categories, and outcomes may vary based on sequence identity, purity, study model, concentration, exposure duration, tissue model, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 20 mg Livagen |
|---|---|
| Primary Solution Volume | 3.0 mL bacteriostatic water |
| Primary Concentration | 6.67 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 6.67 mg/mL, 1 unit equals 0.0667 mg / 66.67 mcg Livagen. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear. Do not shake!
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Livagen, commonly referenced as Lys-Glu-Asp-Ala | Livagen is commonly discussed as a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Ala. |
| Digestive Enzyme Research | Weak hydrolysis / digestive enzyme context | Published research has discussed Livagen in relation to peptide hydrolases of the small intestine and digestive-enzyme interaction models. |
| Peptidase / Enkephalinase Research | Enkephalin-degrading enzyme activity context | Livagen has been studied alongside Epitalon in research involving enkephalin-degrading enzymes from human serum. |
| Bioregulator Research Context | Model-dependent concentration and endpoint tracking | Commonly discussed in peptide bioregulator, tissue-response, enzyme-activity, cellular-aging, protein-synthesis, and gene-expression research contexts. |
| Liver-Associated Research Context | Experimental and model-dependent context | Livagen is often discussed in liver-associated, hepatocyte, cellular-protein-synthesis, metabolic-marker, and age-associated tissue-response research references. |
| Public Protocol-Style Reference | Milligram-range reference examples | Public protocol-style references commonly describe Livagen in milligram-range examples. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 20 mg | 3.0 mL | 6.67 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 6.67 mg/mL | U-100 Unit Reference | Approx. References per 20 mg Vial |
|---|---|---|---|
| 0.5 mg / 500 mcg | 0.08 mL | 7.5 units | 40 |
| 1 mg / 1000 mcg | 0.15 mL | 15 units | 20 |
| 2 mg / 2000 mcg | 0.30 mL | 30 units | 10 |
| 5 mg / 5000 mcg | 0.75 mL | 75 units | 4 |
| 10 mg / 10000 mcg | 1.50 mL | 150 units | 2 |
| 20 mg / 20000 mcg | 3.00 mL | 300 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 7.5 units / 0.08 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 15 units / 0.15 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 30 units / 0.30 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 75 units / 0.75 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 150 units / 1.50 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 300 units / 3.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Enzyme Observation Window | 24–72 hours | May be used for enzyme-activity, protein-synthesis, peptide-hydrolysis, cellular-response, or gene-expression documentation depending on the model. |
| Acute Observation Window | Single session to several days | Used for early response tracking, enzyme-interaction comparison, cellular-marker observation, or short-term peptide-response documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for short-duration controlled observation involving enzyme activity, tissue-response markers, hepatocyte-related endpoints, or age-associated marker documentation. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for protein-synthesis markers, enzyme-response trends, cellular-aging context, or follow-up marker tracking. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Livagen, commonly referenced as Lys-Glu-Asp-Ala, is discussed in peptide bioregulator, digestive-enzyme, peptidase, tissue-response, liver-associated, protein-synthesis, and cellular-aging research contexts. This reference uses a 20 mg vial reconstituted with 3.0 mL bacteriostatic water. Published study references and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Livagen is commonly discussed in research involving ultrashort peptide bioregulation, KEDA tetrapeptide signaling, hepatocyte culture, protein-synthesis activity, digestive enzyme modulation, endogenous peptide metabolism, chromatin dynamics, and cellular aging-marker research.
Study Limitations
Livagen research is limited compared with major peptide categories and includes cell-culture, enzyme-activity, peptide bioregulator, and preclinical references. Findings should be interpreted according to peptide sequence, purity, model type, concentration, exposure duration, and endpoint selection.
Safety Considerations
Research discussion should account for peptide identity verification, KEDA sequence confirmation, sterility documentation, endotoxin risk, supplier qualification, batch records, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.